- Home
- CASI
as 07-26-2024 4:00pm EST
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.
| Founded: | 1991 | Country: | United States |
| Employees: | N/A | City: | N/A |
| Market Cap: | 47.5M | IPO Year: | 1996 |
| Target Price: | $6.00 | AVG Volume (30 days): | 555.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.02 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.90 - $8.48 | Next Earning Date: | 08-09-2024 |
| Revenue: | $33,879,000 | Revenue Growth: | -21.41% |
| Revenue Growth (this year): | 100.27% | Revenue Growth (next year): | -70.24% |
Latest CASI Pharmaceuticals Inc. News
CASI Breaking Stock News: Dive into CASI Ticker-Specific Updates for Smart Investing
PR Newswire
7 days ago
CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS
MT Newswires
19 days ago
CASI Pharmaceuticals Names Daniel Lang CFO
PR Newswire
19 days ago
CASI Pharmaceuticals announces appointment of Daniel Lang, MD as CFO and SVP
Zacks
a month ago
CASI Pharmaceuticals (CASI) Up on Buyout Offer for China Business
MT Newswires
a month ago
Top Premarket Gainers
PR Newswire
a month ago
CASI Pharmaceuticals Announces Plan To Submit IND Application For CID-103, an Anti-CD 38 Antibody in Antibody-Mediated Rejection, and Receipt of a Non-Binding Proposal to Acquire Entire China Business of the Company
PR Newswire
a month ago
CASI Pharmaceuticals Announces $15 Million Private Placement Financing by Venrock Healthcare Capital Partners, Foresite Capital, Panacea Venture and Dr. Wei-Wu He
MT Newswires
2 months ago
CASI Pharmaceuticals Gets FDA Clearance For Blood Disorder Study
Compare CASI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CASI CASI Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.